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Abstract: Immulina®, a high-molecular-weight polysaccharide extract from the cyanobacterium
Arthrospira platensis (Spirulina) is a potent activator of innate immune cells. On the other hand, it is
well documented that Spirulina exerts anti-inflammatory effects and showed promising effects with
respect to the relief of allergic rhinitis symptoms. Taking into account these findings, we decided
to elucidate whether Immulina®, and immunLoges® (a commercial available multicomponent
nutraceutical with Immulina® as a main ingredient) beyond immune-enhancing effects, might also
exert inhibitory effects in the induced allergic inflammatory response and on histamine release from
RBL-2H3 mast cells. Our findings show that Immulina® and immunLoges® inhibited the IgE-antigen
complex-induced production of TNF-α, IL-4, leukotrienes and histamine. The compound 48/80
stimulated histamine release in RBL-2H3 cells was also inhibited. Taken together, our results showed
that Immulina® and immunLoges® exhibit anti-inflammatory properties and inhibited the release
of histamine from mast cells.
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1. Introduction
Arthrospira platensis (Spirulina) is a microscopic and filamentous cyanobacterium. It has a long
tradition of use as food and has been used by humans for many years as food supplement in the form
of health drinks, pills, or tablets. Spirulina became famous after it was used by NASA as a dietary
supplement for astronauts. The safety of Spirulina has been well established. The Food and Drug
Administration (FDA) has categorized Arthrospira products “Generally Recognized as Safe” (GRAS).
Spirulina has high nutritional values due to its high content in proteins (up to 70%), essential amino
acids, minerals, essential fatty acids, vitamins, and antioxidants [1]. Apart from high nutritional values
Spirulina showed hypolipidemic, hypoglycemic, antihypertensive properties, microbial-modulating,
antioxidant and anti-inflammatory activities [2]. In addition, Spirulina may be useful for the treatment
of allergic conditions [3–5]. A prospective study found a high prevalence of Spirulina usage for the relief
of allergic rhinitis symptoms in Turkey [6]. On the other hand, polysaccharides contained in Spirulina
also have immunostimulatory activity. The main active compounds within Immulina®, a commercial
extract of Spirulina, are bacterial Braun-type lipoproteins that activate innate immune cells through a
toll-like receptor (TLR) 2-dependent pathway [7]. Previous studies indicate that Immulina® is a potent
in vitro [8,9] and in vivo [10,11] immune cell activator. In addition, Immulina® can exhibit a protective
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effect against influenza A (H1N1) viral infection [12]. Immulina® which has been commercialized as a
dietary supplement for modulating immune function, as well as ameliorating various diseases, is also
an ingredient of multicomponent-nutraceuticals e.g., of immunLoges®.
Macrophages are an important component of the innate immune system and clear organisms
through their phagocytic function. Toll-like receptors expressed by macrophages play an important role
in their activation. Macrophages at tissue sites of allergic inflammation originate from mononuclear
cells in the bone marrow. In addition to their phagocytic and antigen presenting role, macrophages have
the potential to be proinflammatory or anti-inflammatory based on the spectrum of mediators
they can release. There are two major pathways of the macrophage activation required for their
main functional activities: the classical M1 pathway and the alternative M2 pathway [13,14].
The classical pathway gives rise to the M1 macrophages during an immune response to infection
and is mediated by the Th1 cytokine interferon gamma (IFN-γ) and the toll-like receptor agonists,
such as lipopolysaccharide (LPS). IL-17 also modulates the differentiation of macrophages to the
pro-inflammatory M1 phenotype [15]. The classically activated M1 macrophages express and secrete
large amounts of potent pro-inflammatory mediators such as tumor necrosis factor (TNF) and reactive
oxygen species. Moreover, the M1 macrophages express high levels of major histocompatibility
complex (MHC) class II and, co-stimulatory molecules, such as CD86, which are important for the
activation and stimulation of CD4 T cells. The alternatively activated M2 macrophages are induced
by the Th2-derived cytokines IL-4 or IL-13 (IL-4/IL-13-induced phenotype is also called the “M2a”
subset of M2 population). The M2 macrophages produce a number of factors that are responsible for
the anti-parasitic response and promote tissue repair such as Fizz1, Ym1, Arg1, Mannose Receptor
(MR or CD206) as well as anti-inflammatory, regulatory, and B cell-stimulating factors such as TGF-β1,
IL-4, and IL-10 [14,16].
Allergic airway diseases, such as asthma and allergic rhinitis, are common diseases caused
by hypersensitivity of the immune system. Approximately 10–20% of the world population is affected
by allergies, with the number of allergy patients increasing annually [17,18]. Most allergy patients
are genetically predisposed to produce IgE. Mast cells play an important role in innate and adaptive
immunity, especially in allergic and inflammatory responses. Mast cells express a high-affinity IgE
receptor on membranes, and the binding of IgE-antigen complexes to the FcεRI (high-affinity receptor
for the Fc region of immunoglobulin E) receptor triggers complex biological reactions. Activation of
rat basophilic leukemia cells (RBL-2H3) cells by an IgE-antigen complex induced the production of
TNF-alpha and IL-4. Mast cells are a key player in early allergic response, which typically occurs within
minutes of exposure to an appropriate antigen, and other biological responses, including inflammatory
disorders [19]. These cells are critical effector cells in IgE-dependent immediate hypersensitivity
reactions [20]. Mast cell degranulation can initiate an acute inflammatory response and contribute
to the progression of chronic diseases [21]. When an IgE-antigen binds with FcεRI, the receptor
is activated, and a variety of biologically active mediators are released, causing allergic reactions,
including the release of histamine, arachidonic acid metabolites, and inflammatory cytokines [22].
Importantly, arachidonic acid metabolites, including prostaglandins and leukotrienes, mediate acute
and chronic allergic reactions [23,24]. RBL-2H3 cells are a mast cell line that originated from rat
basophilic leukemia and have been widely used to study IgE-FcεRI interactions and degranulation.
Furthermore, RBL-2H3 cells are a useful model for in vitro screening of antiallergy drug candidates.
The aim of the present study was to determine whether Immulina® despite its well documented
immunostimulatory activity and/or immunLoges®, also have anti-inflammatory activities and may be
useful for the treatment of allergic conditions.
Plants 2018, 7, 13 3 of 14
2. Results
2.1. Cytotoxicity Effects of Immunloges® and Immulina® in Raw264.7 Cells
To analyze the potential cytotoxic activities of the test substances Raw264.7 cells were incubated
with increasing concentrations of immunLoges® and Immulina® for 24 and the cytotoxicity
was measured by YOYO-1 staining and fluorescence microscopy using an Incucyte System.
Only immunLoges® at the highest concentration tested (1000 µg/mL) showed cytotoxicity at 24 h
(Figure 1). After analyzing the potential cytotoxicity in primary cells, it was decided to use the
concentrations described in Material and Methods.
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Figure 1. Cytotoxic activity of im unLoges® and I ulina® in Raw264.7 cells. The cells were treated
with immunLoges® (A) or Immulina® (B) at the indicated concentrations for 24 h. Cytotoxicity was
measured by fluorescence microscopy using an Incucyte System. Data represent the mean ± SD (n = 3).
*** p < 0.001 vs. untreated. (one-way analysis of variance (ANOVA) followed Newman-Keuls test).
2.2. NF-kB Activation in Raw264.7 Cells
Although previous studies indicate that Immulina® is a potent i vitro and in vivo immune
cell activator, we wanted to know the activity of the commercial extract immunLoges®. In this
sense we evaluated the effect of the active component and the comm rcial extract on the NF-κB
transcriptional activity. This activity was evaluated by using the luciferase reporter construct
KBF-Luc [25]. Activation by LPS clearly increased (13-fold induction) the luciferase gene expression
driven by the NF-κB dependent promoter in stably transfected Raw264.7 cells. We found that,
immunLoges® and Immulina® increase this activity (Figure 2A,B).
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Figure 2. NF-kB activity of immunLoges® (A) and Immulina® (B) in Raw264.7-KBF-Luc cells.
Cells were pre-incubated with the test substances at the indicated concentrations for 30 min and
then stimulated with LPS for 6 h. The results of the specific transactivation are expressed as a fold
induction over untreated cells. Data represent the mean ± SD (n = 3). *** p < 0.001 vs. untreated,
# p < 0.05, ## p < 0.01 vs. LPS treatment. (one-way ANOVA followed Newman-Keuls test).
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2.3. Effect of Immunloges® and Immulina® on M1 and M2 Polarization
Macrophages are also important effector cells that mediate the immune responses. They act as
antigen presenting cells (APC), thereby activating an antigen-specific T cell response in the periphery
and central nervous system (CNS). Macrophages detect the endogenous danger signals that are present
in the debris of necrotic cells through Toll-like receptors (TLRs) 2,6,intracellular pattern-recognition
receptors and the interleukin-1 receptor (IL-1R), most of which signal through the adaptor molecule
myeloid differentiation primary-response gene 88 (MyD88). This function makes macrophages one of
the primary sensors of danger in the host.
Treatment of RAW264.7 macrophages with IL-17 promoted their polarization towards a
pro-inflammatory M1 phenotype, as shown by increased expression of M1 markers such as TNF-α,
CCL2 or IL-1β. Raw264.7 cells were pre-treated for 18 h with the test substances and then were exposed
to recombinant murine IL-17 to induce M1 polarization and M1 markers were analyzed by qPCR. The
treatment with immunLoges® and Immulina® clearly enhanced the expression of IL17-induced M1
markers TNF-α, CCL2 and IL-1ß as shown in Figure 3.
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Figure 3. Effect of immunLoges®, Immulina® on IL-17-induced M1 markers expression. Cells were
pre-incubated with immunLoges® or Immulina® at the indicated concentrations for 18 h and then
stimulated with IL-17 for 24 h. TNF-α (A,B), CCL2 (C, ) and IL-1β (E,F) expression as deter ined.
The GAP gene as used to standardize mRNA expression in each sample and gene expression was
quantified using the 2-∆∆Ct method. Data represent the mean ± SD (n = 3). * p < 0.05 vs. untreated,
# p < 0.05, ## < 0.01, ### p < 0. 01 vs. IL-17 treatment. (one-way ANOVA f llowed Newman-Keuls test.
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To study the effect of immunLoges® and Immulina® on M2 polarization, Raw264.7 cells were
treated for 24 h with the test substances at the indicated concentrations. As positive control we used
the recombinant mouse IL-4 to induce M2 polarization. M2 markers such as Arg1, Mrc1 and IL-10
were determined. The treatment with immunLoges® and Immulina® clearly induced the expression of
the M2 markers Arg1 (Figure 4A,B), and Mrc1 (Figure 4C,D). In the case of IL10 gene expression, the
treatment did not impair the gene expression (Figure 4E,F).
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Figure 4. Effect of immunLoges®, Immulina on 2 polarization. Cells were pre-incubated with
immunLoges® or Immulina® at the indicated concentrations for 24 h. Arg-1 (A,B), Mrc-1 (C,D) and
IL-10 (E,F) expression was determined. The GAPDH gene was used to standardize mRNA expression
in each sample and gene expression was quantified using the 2-∆∆Ct method. Data represent the mean
± SD (n = 3). * p < 0.05, *** p < 0.001 vs. untreated. (one-way ANOVA followed Newman-Keuls test).
2.4. Cytotoxicity Effects of Im unloges® and I li a® in RBL-2H3 Cells
To evaluate the cytotoxicity of im unLo and Immulina® on RBL-2H3, the cells were
treated with different concentrations for 24 h and the cytotoxicity was measured by fluorescence
microscopy using an Incucyte System. Neither Immulina® nor immunLoges® showed cytotoxicity at
the concentrations investigated in this study (Figure 5).
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Figure 5. Cytotoxic activity of immunLoges® (A) and Immulina® (B) in RBL-2H3 cells. The cells were
treated with immunLoges® or Immulina® at the indicated concentrations for 24 h. Cytotoxicity was
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2.5. Effect on Cytokines Release in IgE-Antigen Co le ti ulated RBL-2H3 Cells
Mast cells express a high-affinity IgE rece cεRI) on membranes, and the binding of
IgE-antige complexes to FcεRI triggers complex i l ical reactions. RBL-2H3 cells were sensitized
with anti-DNP-IgE (monoclonal anti-dinotrophenyl antibody produced in mouse, IgE isotype) and
stimulated with DNP-HSA (dinitrophenyl-human serum albumin). Inflammatory cytokines mediate
the pathological reaction in inflammatory diseases. Besides the secretion of stored cytokines during
degranulation, the production of newly generated inflammatory cytokines (TNF-α, IL-4, IL-6 etc.)
is induced.
The effects of the test substances on pro-inflammatory cytokine production were assessed
by ELISA. Activation of RBL-2H3 cells by an IgE-antigen c mplex i duced th pro uction of TNF-α
and IL-4. The treatme t with immunLoges® (Figure 6A) or Immulina® (Figure 6B) decreased the levels
of TNF-α and IL-4 (Figure 6C,D) in FcεRI-activated RBL-2H3 cells.
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complex-stimulated RBL-2H3 cells. The c lls were treated with i munLoges® (A,C) or I mulina®
(B,D) at the indicated concentrations and the levels of TNF-α and IL-4 were determined in
the supernatants. Data represent the mean ± SD (n = 3). *** p < 0.001 vs. Anti-DNP-IgE, ### p < 0.001
vs. Anti-DNP-IgE+DNP-HAS treatment. (one-way ANOVA followed Newman-Keuls test).
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2.6. Effect on Leukotrienes Production in IgE-Antigen Complex-Stimulated RBL-2H3 Cells
In parallel to the analysis of cytokine production we determined the formation of leukotrienes
LTC4/D4/E4 in supernatants of IgE-antigen complex-stimulated RBL-2H3 cells. The treatment with
immunLoges® (Figure 7A) and Immulina® (Figure 7B) reduced the levels of leukotrienes.
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2.7. Effect on the Release of Histamine in IgE-Antigen o plex-Sti ulated RBL-2H3 Cells
Optimum conditions for IgE mediated degranulation in RBL-2H3 cells were sensitizing with
anti-DNP-IgE and stimulating with 2,4-Dinitrophenyl hapten conjugated to human serum albumin
(DNP-HSA). The release of histamine in IgE-antigen complex-stimulated RBL-2H3 cells were
significantly increased compared with untreated cells. Pre-treatment for 2 h with the test substances at
the indicated concentrations clearly suppressed the degranulation in IgE-antigen complex-stimulated
RBL-2H3 cells. In addition, we tested the mast cell stabilizing agent Disodium cromoglycate (DSCG).
As it is shown in Figure 8 the treatment with this compound inhibited the degranulation in a similar
manner to that observed for immunLoges® (Figure 8A) and Immulina® (Figure 8B).
The effects of synthetic compound 48/80 were also examined, since earlier studies have shown
that this compound is a very potent inducer of mast cell degranulation. Compound 48/80 is a G
protein stimulant compound originally described as a mast cell secretagogue. Pre-treatment for 2 h
with the compounds at the indicated concentrations inhibited the release of histamine from RBL-2H3
stimulated by compound 48/80 (Figure 8 C,D).
Finally, we determined the effect of immunLoges® and Immulina® on the basal release
of histamine in the mast cell line. The treatment with the test substances at the concentrations
investigated did not induce histamine secretion (Figure 9).
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Figure 8. Effect of immunLoges® and Immulina® on mast stabilization. The cells were pretreated for
2 h with immunLoges® (A,C) and Immulina® (B,D) at the indicated concentrations and stimulated as
indicated. The levels of histamine were determined in the supernatants. Data represent the mean ± SD
(n = 3). *** p < 0.001 vs. Anti-DNP-IgE or untreated cells, ### p < 0.001 vs. Anti-DNP-IgE+DNP-HAS or
48/80 treatment. (one-way ANOVA followed Newman-Keuls test).
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Figure 9. Effect of immunLoges® and Immulina on mast stabilization. The cells were treated for 2 h
with immunLoges® (A) and Immulina® (B) at the indicated concentrations. The levels of histamine
were determined in the supernatants. Data represent the mean ± SD (n = 3). *** p < 0.001 vs. untreated
cells (one-way ANOVA followed Newman-Keuls test).
3. Discussion
Previous reports sh wed that Immulina® is a potent immune cell activator and activates NF-kB
through TLR2 receptor [7,8]. Here w describ the activation of NF-kB in macrophages treated with
immunLoges® and Immulina® in the presence f LPS c nfirming those previous studies. Herein we
show that immunLoges® preserves the immunomodulatory activity.
Traditionally, macrophages have been seen only as immune cells, and their homeostatic
responsibilities have been overlooked. Mosser et al. [26], proposed that macrophages exist in three
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main categories: host defense, wound healing, and immune regulation. M1 macrophages (classically
activated) clears tissue of cellular debris and pathogens via aggressive phagocytosis and release of
pro-inflammatory cytokines including: IL-1, IL-6, IL-12, IL-23, and TNF-α. The M2 macrophage acts as
a support cell by promoting the healing of damaged cells by angiogenesis and tissue remodeling via
secretion of anti-inflammatory cytokines. While these two operationally useful polarities exist, it is
widely believed that macrophages exist mainly in the continuum between these two phenotypes [27].
Regulation of this continuum involves complex processes that have been extensively studied, yet
remain relatively unclear. Recently it was shown that macrophages will respond to injury or infection
by upregulating pro-inflammatory (M1) responses, but later switch to an anti-inflammatory (M2)
response once the infection is under control [28,29]. This M1 activation program is typically associated
with protection against disease, and M1 polarization has been shown to aid host control of several
bacteria, including Listeria monocytogenes, Salmonella typhimurium, Mycobacterium tuberculosis
and Chlamydia infections [30–32].
Here we describe a dual role for immunLoges® and Immulina® in the macrophage polarization.
On the one hand, we observed an increase of M1 markers such as TNF-α, CCL2 and IL-1β in the
presence of LPS. This effect on M1 polarization is important from the point of view of the common
response of macrophages to bacterial infections which mainly involve the up-regulation of genes
involved in M1 polarization. Moreover, other M1 associated up-regulated genes encode the enzymes
indoleamine-pyrrole 2,3 dioxygenase and NO synthase 2 (NOS2), which are related with macrophage
microbicidal activity [30]. The effect of immunLoges® and Immulina® on M2 polarization could
be related with immunoregulatory activity since M2 macrophages dampen inflammation, suppress
antitumor immunity and promote wound healing and tissue remodeling.
Although more sophisticated mechanisms are still unknown, data from animal studies suggest
that mast cells act similarly to macrophages and other inflammatory cells and contribute to human
diseases through cell–cell interactions and the release of proinflammatory cytokines, chemokines, and
proteases to induce inflammatory cell recruitment. There is growing interest in understanding how
mast cells participate in positive immunoregulation particularly in the innate aspects of an immune
response [33–35].
Mast cells are important in innate immune system. They have been appreciated as potent
contributors to allergic reaction. Mast cells have a widespread distribution and are found
predominantly at the interface between the host and the external environment and acted as both
first responders in harmful situations as well as to respond to changes in their environment by
communicating with a variety of other cells implicated in immunological responses. Therefore, the
critical role of mast cells in both innate and adaptive immunity, including immune tolerance, has
gained increased prominence [36–38]. Conversely, mast cell dysfunction has pointed to these cells
as the main offenders in several chronic allergic/inflammatory disorders, cancer, and autoimmune
diseases [39–41].
Moreover, it has been well documented that Spirulina exhibits anti-inflammatory properties by
inhibiting the release of histamine from mast cells [3]. In a randomized double-blind placebo-controlled
trial individuals with allergic rhinitis Spirulina significantly reduced the levels of IL-4 that is important
in regulating immunoglobulin (Ig)E-mediated allergy [5].
Since high molecular weight polysaccharides are present in Immulina® it is possible that different
preparations of these algae may exert different immunological activities. Immulina® and immunLoges®
decreased the levels of TNF-α and IL-4 in FcεRI-activated RBL-2H3 cells. These results indicated the
anti-allergic property of both substances in allergic inflammation therapy.
In parallel to the analysis of cytokine production we tested the release of leukotrienes, which
are important mediators both in host defense mechanisms and in inflammatory disease states.
Leukotrienes can be formed in mast cells, granulocytes, and monocytes/macrophages in response to
extracellular stimulation. In this study, we determined the formation of leukotrienes LTC4/D4/E4
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in supernatants of IgE-antigen complex-stimulated RBL-2H3 cells. The treatment with Immulina®
reduced the levels of leukotrienes.
Apart from the anti-inflammatory parameters we also investigated the effects on mast cell
stabilization and histamine release. Immulina® inhibited the release of histamine in IgE-antigen
complex-stimulated RBL-2H3 cells in a similar manner to that observed for the mast cell stabilizing
agent Disodium cromoglycate (DSCG). In addition, we determined the effect of the test substances
on the secretion of histamine induced by compound 48/80. This G protein stimulant compound was
originally described as a mast cell secretagogue. Again, Immulina® inhibited the compound 48/80
stimulated histamine release in RBL-2H3 cells.
In parallel we tested immunLoges® in the above-mentioned assays and immunLoges® showed
similar effects compared to Immulina®. Therefore, neither additional compounds (vitamins etc.) nor
excipients in immunLoges® interfered with the described activities.
Immulina® is a patented, high molecular weight polysaccharide extract from spirulina and the
predominant active compounds are Braun-type lipoproteins. Although Immulina® is a potent NF-kB
and immune cell activator, our results clearly showed that Immulina® has anti-inflammatory and
anti-histaminic effects in RBL-2H3 cells.
In general, the results obtained for both products, Immulina® and immunLoges®, are
dose-response independent, which can be explained by the fact that most of the studies for both
compounds had strong activity at the lowest concentrations studied.
Overall, our results with Immulina® and immunLoges® agree with the concept that Spirulina
exerts anti-inflammatory effects and may be useful for the treatment of allergic conditions, but further
in vivo studies should be performed to clarify these effects for Immulina® and immunLoges®.
4. Materials and Methods
4.1. Test items
Immulina® is a patented extract [22] derived from Arthrospira platensis (Nordstedt) Gomont,
Phormidiaceae (previously called Spirulina platensis and commonly known as Spirulina). This extract
represents a 10–15% yield from spray dried Arthrospira platensis and is standardized by biological
activity to ensure consistent activity of the extract from batch to batch. Biological standardization is
performed using a humanTHP-1 monocyte activation assay that measures activity as indicated by
increased expression of an NF-kB-driven luciferase reporter as previously described (Pugh et al. 2001).
The Immulina® extract (batch number 600137) used in this research was supplied by ChromaDex Inc.
(Irvine, CA, USA). immunLoges® (batch 500875, Dr. Loges + Co. GmbH, Winsen, Germany) is a
multi-complex formulation of Immulina®, Betox 93®, Selenium, Zink, Vitamin C, D and resveratrol.
One tablet immunLoges® (420 mg) contains among others 200 mg Immulina®. The composition of
commercial extract for ImmunLoges® is described in the Table 1 below. For a better comparison of the
results, we tested the immunLoges® concentration which correspond to the Immulina® concentration
in immunLoges®. The stock solutions were prepared in DMSO and then diluted in cell culture media.
The final DMSO concentration never exceeded 0.1% (v/v).
Table 1. Composition of commercial extract immunLoges®. The composition of immunLoges® per
capsule is indicated in the table. Excipients (54.5 mg) such as cellulose, talcum and magnesium.
Composition Per Capsule
Immulina® 200 mg
Betox 93® 60 mg
Vineatrol® 0.5 mg
Vitamin C 40 mg
Vitamin D 10 µg
Selenite 50 µg
Zinc 5 mg
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4.2. Cell Culture
RAW264.7 mouse macrophage cell line was obtained from ATCC (TIB-71) and maintained at
37 ◦C in a humidified atmosphere containing 5% CO2 in (Dulbecco’s Modified Eagle Medium)
(DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and 1% (v/v)
penicillin/streptomycin. Raw264.7-kappaB Factor (KBF)-Luc cell line is stably transfected cell line
with the KBF-Luc plasmid that contains the luciferase gene driven by an artificial promoter made
by 3 multimerized copies of the NF-kB binding site from the MHCI Class I promoter. These cells
were maintained in DMEM medium supplemented with antibiotics and 10% heat-inactivated FBS.
The rat basophilic leukemia cell line RBL-2H3 was obtained from ATCC (CRL-2256) and grown
in Dulbecco’s modified Eagle medium with 100 IU/mL penicillin, 100 mg/mL streptomycin, and
10% heat-inactivated fetal calf serum (FCS) in a humidified 5% CO2 atmosphere at 37 ◦C.
4.3. Cytotoxicity
To identify non-cytotoxic concentrations of the test items RAW264.7 or RBL-2H3 cells were
treated with increasing concentrations of the test compounds for 24 h. Cytotoxicity was measured by
fluorescence (Essen BioScience, Inc., Ann Arbor, MI, USA) using YOYO-1, purchased from Thermo
Fisher Scientific (Waltham, MA, USA), is a green fluorescent dye used in DNA staining. The dye was
diluted in cell cultured medium and added to a final concentration of 0.1 µM.
After 3–4 h the total number of DNA containing objects was measured by treating cells with
0.0625% triton X-100 to permeabilize the cell membrane. Object counting analysis was performed using
the Incucyte FLR software (Essen BioScience, Inc., Ann Arbor, MI, USA) to calculate the total number
of YOYO-1 fluorescence positive cells and total DNA containing objects (end point). The cytotoxicity
index was calculated by dividing the number of YOYO-1 fluorescence positive objects by the total
number of DNA containing objects for each treatment group.
4.4. NF-kB Activation in Raw264.7-KBF-Luc Cells
To study the potential NF-kB modulatory activity of the test items we used the stably transfected
Raw264.7-KBF-Luc cell line. Cells were pretreated with the test substances for 30 min and then were
stimulated with LPS for 6 h. In addition, cells were treated with the test compounds in the absence
of LPS. Then the cells were washed and lysed in 25 mM Tris-phosphate pH 7.8, 8 mM MgCl2, 1 mM
DTT, 1% Triton X-100, and 7% glycerol. Luciferase activity was measured using an Autolumat LB 953
(EG&G Berthold, Oak Ridge, TN, USA) following the instructions of the luciferase assay kit (Promega,
Madison, WI, USA). The results of the specific transactivation are expressed as a fold induction over
untreated cells.
4.5. IL-17-Induced M1 Polarization
Serum-starved Raw264.7 macrophages were pre-incubated with increasing concentrations of
the test compounds for 18 h, before an additional 24-h treatment with the recombinant mouse IL-17
(100 ng/mL). Then cells were collected and total RNA extracted using the High Pure RNA Isolation kit
(Roche Diagnostics, Hong Kong, China). Total RNA (1 µg) was retrotranscribed using the iScriptTM
cDNA Synthesis Kit (Bio-Rad; Hercules, CA, USA), and the cDNA generated analyzed by real-time
PCR, using the iQTM SYBR Green Supermix (Bio-Rad; Hercules, CA, USA). Real-time PCR was
performed using a CFX96 Real-time PCR Detection System (Bio-Rad; Hercules, CA, USA). The GAPDH
gene was used to standardize mRNA expression in each sample and gene expression was quantified
using the 2-∆∆Ct method. The markers analyzed for M1 polarization were TNF-α, CCL2 and IL-1ß.
4.6. IL-4-Induced M2 Polarization
Serum-starved Raw264.7 macrophages were pre-incubated with increasing concentrations of
the test compounds for 24 h. As positive control for M2 polarization we treated the cells with the
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recombinant mouse IL-4 (20 ng/mL) for 24 h. Then cells were collected and total RNA extracted
using the High Pure RNA Isolation kit (Roche Diagnostics, Hong Kong, China). Total RNA (1 µg)
was retrotranscribed using the iScriptTM cDNA Synthesis Kit (Bio-Rad; Hercules, CA, USA), and
the cDNA generated analyzed by real-time PCR, using the iQTM SYBR Green Supermix (Bio-Rad;
Hercules, CA, USA). Real-time PCR was performed using a CFX96 Real-time PCR Detection System
(Bio-Rad; Hercules, CA, USA). The GAPDH gene was used to standardize mRNA expression in each
sample and gene expression was quantified using the 2-∆∆Ct method. The markers analyzed for M2
polarization were Arg1, IL-10 and Mrc1.
4.7. Detection of Leukotrienes and Cytokines in RBL-2H3 Cells
RBL-2H3 cells were seeded at 2 × 105 cells in 24-well plates and after 24 h cells were
incubated overnight with or without anti-DNP IgE mAb (Santa Cruz Biotechnology, Dallas, TX,
USA) (0.5 µg/mL) for sensitization. Next, cells were pre-incubated with the test substances for 1 h
and then stimulated with DNP-HSA (Santa Cruz Biotechnology) (200 ng/mL) for 3 h. Supernatants
were collected, centrifuged for 10 min at 400× g (4 ◦C) and the leukotrienes (LTC4/D4/E4), IL-4
and TNF-α were analyzed. Leukotrienes kit was obtained from Enzo Life Sciences (New York, NY,
USA) IL-4 and TNF-α ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA).
The levels of leukotrienes and cytokines were analyzed with plate-bound ELISA kits according to the
manufacturer’s recommendations.
4.8. Detection of Histamine Release in RBL-2H3 Cells
RBL-2H3 cells were seeded at 2 × 105 cells in 24-well plates and after 24 h the medium in each
well was aspirated and replaced by fresh medium. Next cells were pre-incubated with the compounds
for 2 h and then were stimulated with the compound 48/80 (25 µg/mL) (Sigma Aldrich, St. Louis,
MO, USA) in the presence or absence of non-cytotoxic concentrations of the test substances for 15 min.
After treatment, supernatants were collected and centrifuged for 10 min at 400× g (4 ◦C). Histamine
Elisa Fast Track was purchased from LDN GmbH, Germany. Histamine in the supernatant was
determined by an ELISA assay according to the manufacturer’s recommendations.
4.9. RBL-2H3 Mast Cells Stabilization
RBL-2H3 cells were seeded at 2 × 105 cells in 24-well plates and after 24 h cells were
incubated overnight with or without anti-DNP IgE mAb (0.5 µg/mL) for sensitization. Next, cells
were pre-incubated with the test substances or the well-known mast stabilizing agent Disodium
cromoglycate (DSCG) for 2 h and then stimulated with DNP-HSA (1 µg/mL) for 30 min. Supernatants
were collected, centrifuged for 10 min at 400× g (4 ◦C) and histamine release was determined as
above described.
4.10. Statistical Analysis
Data were analyzed by one-way analysis of variance (ANOVA) followed by Newman Keuls
post-hoc test using GraphPad Prism version 6.00 (GraphPad, San Diego, CA, USA). Results were
presented as means ± SD and differences were considered significant when p < 0.05.
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